Rising Trends: Point-of-Care Opioid Testing Market Anticipates US$725.1 Million in 2033

By 2023, it is anticipated that the point-of-care opioid testing market would be valued at US$ 450.9 million. Through 2033, the market is expected to have grown at a 4.9% CAGR and reach US$ 725.1 million. The growing opioid epidemic, rising public awareness of drug use, and the need for efficient testing methods have all contributed to the recent spectacular growth in the point-of-care opioid testing industry. As long as there is a need for rapid and precise drug test solutions, it is projected that the market will expand.

The demand for point-of-care opioid testing is expected to continue rising due to the ongoing opioid epidemic and the need for effective monitoring and intervention. Governments, healthcare providers, workplaces, and law enforcement agencies are increasingly recognizing the importance of rapid and accurate drug testing to address the crisis. This demand will be a significant driver for market growth.

Unleash Your Potential: Experience Unparalleled Excellence with Our Sample:https://www.futuremarketinsights.com/reports/sample/rep-gb-17625

Advancements in testing technologies, including immunoassays, biosensors, molecular diagnostics, and digital health platforms, are enhancing the performance, sensitivity, specificity, and connectivity of point-of-care opioid testing devices. These technological innovations improve the accuracy, speed, and user experience of testing, driving market growth and adoption.

Point-of-care opioid testing is expanding beyond traditional healthcare settings, such as hospitals and clinics, into non-traditional settings like workplaces, home care, and telehealth. The convenience and accessibility of testing in these settings address the need for decentralized healthcare and patient-centric testing, creating new market opportunities.

Key Takeaways:

The point-of-care opioid testing industry in the United States is predicted to reach US$ 227.4 million by 2033, increasing at a 4.2% CAGR.
The point-of-care opioid testing industry in the United Kingdom is estimated to reach a market value of US$ 32.0 million, expanding at a CAGR of 4.3% by 2033.
During the forecast period, the point-of-care opioid testing industry in China is expected to reach a market value of US$ 54.7 million, securing a 6.4% CAGR.
The point-of-care opioid testing industry in Japan is predicted to reach US$ 39.9 million by 2033, increasing at a 6.2% CAGR.
During the forecast period, the point-of-care opioid testing industry in South Korea is expected to reach a market value of US$ 45.4 million, securing a 6.0% CAGR.
With a CAGR of 4.7% from 2023 to 2033, the test strips is expected to dominate the point-of-care opioid testing industry.
With a CAGR of 5.2% from 2023 to 2033, the Multi-panel drug test kits is expected to dominate the point-of-care opioid testing industry.
With a CAGR of 4.9% from 2023 to 2033, the Blood sample is expected to dominate the point-of-care opioid testing industry.
With a CAGR of 5.4% from 2023 to 2033, the forensic laboratories is expected to dominate the point-of-care opioid testing industry.

Key Players:

Avon Healthcare
Triveni Traders Diagnostic Private Limited
AdvaCare Pharma USA
BTNX Inc.
Phamatech
ADC
Worldwide Medical Corporation
Accu-Stat Diagnostics, Inc
ACON Laboratories, Inc.
Alere
Innovacon, Inc.
Amedica Biotech, Inc
Branan Medical Corporation
Biosite Inc
UCP Biosciences, Inc
TransMed Company
Vitrosens Biotechnology
Abbot
clarity diagnostics
Alcotec Company Limited

Key Developments:

In November 2022, Abbott receives three CES 2023 Innovation awards for advancements in health technology.
In August 2019, Intoximeters and Abbott recently established a partnership to commercialise Abbott’s SoToxaTM Mobile Test System, a portable oral fluid roadside testing device that accurately and quickly identifies recent drug use.

Key Segmentation

By Product: